TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10564677

Group type: EXPERIMENTAL
Intervention: African-American patients
Number of subjects: 663

Group type: COMPARATOR
Intervention: Caucasian patients
Number of subjects: 663
Study: 7747682

Group type: EXPERIMENTAL
Intervention: d-sotalol (200 mg/day)
Number of subjects: 6400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6400
Study: 2117891

Group type: EXPERIMENTAL
Intervention: Intraperitoneal administration of recombinant interferon-beta (IFN-beta) at 6 x 10(6) units continuously for 14 days from the day of operation.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group received MMC, 20 mg (i.v.) on the day of operation and 5-FU, 200 mg (p.o.) for 1 year from 2 weeks after operation.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Both groups were compared for 3-year survival rate and disease-free survival rate.
Number of subjects: 33
Study: 6895415

Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy + MOPP
Number of subjects: 3

Group type: COMPARATOR
Intervention: Involved-field radiotherapy
Number of subjects: 3

Group type: COMPARATOR
Intervention: Extended-field radiotherapy
Number of subjects: 3

Group type: COMPARATOR
Intervention: Radiotherapy alone for limited mediastinal disease
Number of subjects: 3

Group type: COMPARATOR
Intervention: Radiotherapy alone for extensive mediastinal and hilar disease
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: MOPP alone
Number of subjects: 3
Study: 30660733

Group type: EXPERIMENTAL
Intervention: Statin exposure (new initiators)
Number of subjects: 73944

Group type: EXPERIMENTAL
Intervention: Statin exposure (existing users)
Number of subjects: 73944

Group type: COMPARATOR
Intervention: Baseline total cholesterol increase (statin-naïve subjects)
Number of subjects: 73944

Group type: EXPERIMENTAL
Intervention: Statin exposure (cumulative years)
Number of subjects: 73944
Study: 28567578

Group type: EXPERIMENTAL
Intervention: Multiple-dose intravenous tranexamic acid (IV-TXA) - one bolus before skin incision, two boluses at 3 and 6 hours later (group A)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Multiple-dose intravenous tranexamic acid (IV-TXA) - one bolus before skin incision, one bolus at 9 hours later (group B)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Multiple-dose intravenous tranexamic acid (IV-TXA) - one bolus before skin incision, two boluses at 9 and 12 hours later (group C)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 159
Study: 26458939

Group type: EXPERIMENTAL
Intervention: Dalbavancin 1000 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dalbavancin 500 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 23433688

Group type: EXPERIMENTAL
Intervention: 600 mg/day of DHA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo oil capsules
Number of subjects: 0
Study: 21243486

Group type: EXPERIMENTAL
Intervention: 1 mg nasal nicotine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 20031736

Group type: EXPERIMENTAL
Intervention: Heparin plus eptifibatide
Number of subjects: 400

Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 400
Study: 17044132

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI)
Number of subjects: 2729

Group type: COMPARATOR
Intervention: Geriatric Depression Scale (GDS)
Number of subjects: 2729
Study: 15117090

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg
Number of subjects: 355

Group type: COMPARATOR
Intervention: Rofecoxib 50 mg
Number of subjects: 355

Group type: COMPARATOR
Intervention: Celecoxib 200 mg
Number of subjects: 355

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study: 11673582

Group type: EXPERIMENTAL
Intervention: Low-dose vigabatrin (18-36 mg/kg/day)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: High-dose vigabatrin (100-148 mg/kg/day)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: High-dose vigabatrin
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Patients with tuberous sclerosis
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Vigabatrin (both doses)
Number of subjects: 142
Study: 9502190

Group type: EXPERIMENTAL
Intervention: euglycaemic clamp [glucose 5 mmol L(‐1)]
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: hyperglycaemic clamp [glucose 15 mmol L(‐1)]
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: euglycaemic hyperinsulinaemic clamp [glucose 5 mmol L(‐l)]
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: intrajejunal infusion of lipid (Lipofundin medium‐chained triglyceride 10%)
Number of subjects: 9

Group type: COMPARATOR
Intervention: exogenous or endogenous hyperinsulinaemia
Number of subjects: 9
Study: 7857119

Group type: EXPERIMENTAL
Intervention: Docetaxel (RP 56976)
Number of subjects: 12
Study: 2122343

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 354372

Group type: EXPERIMENTAL
Intervention: Piperazine (ascaricide)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 30124725

Group type: EXPERIMENTAL
Intervention: Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 212

Group type: COMPARATOR
Intervention: Tazarotene (TAZ)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Halobetasol (HP)
Number of subjects: 212
Study: 26205759

Group type: EXPERIMENTAL
Intervention: Tacrolimus with oral prednisolone (TAC*)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Modified Ponticelli regimen (MPR)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cyclical CTX/steroids (MPR)
Number of subjects: 70
Study: 24604685

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) combined with methylprednisolone (MPred) - EPO dosage: 20,000 U/24 h, MPred dosage: 1,000 mg/24 h for five consecutive days.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Methylprednisolone (MPred) alone - MPred dosage: 1,000 mg/24 h for five consecutive days, placebo for EPO.
Number of subjects: 20
Study: 23048057

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting bioresorbable vascular scaffold
Number of subjects: 45
Study: 20410083

Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (10 mg iron, 375 microg vitamin A, 4.2 mg zinc, 225 microg folic acid, 1.35 microg vitamin B-12 per child per day)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Multiple micronutrients
Number of subjects: 499
Study: 18417532

Group type: EXPERIMENTAL
Intervention: Salmonella enterica serovar Typhi Ty21a expressing H pylori urease or HP0231
Number of subjects: 58

Group type: COMPARATOR
Intervention: Ty21a (control)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Overall (both vaccinees and controls)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: T cell response
Number of subjects: 58
Study: 16040923

Group type: EXPERIMENTAL
Intervention: iohexol [300 mg of iodine per milliliter]
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: iodixanol [320 mg I/mL]
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: iohexol [350 mg I/mL]
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: iomeprol [350 mg I/mL]
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: iomeprol [400 mg I/mL]
Number of subjects: 125
Study: 12930007

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.2 mg
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.25 mg
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.3 mg
Number of subjects: 343

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 343
Study: 10230955

Group type: EXPERIMENTAL
Intervention: Phentolamine (0.2 mg/kg) during cooling and rewarming periods of CPB
Number of subjects: 43
Study: 8681614

Group type: EXPERIMENTAL
Intervention: Nasal-CPAP (N-CPAP)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Surgery (uvulopalatopharyngoplasty [UPPP] with or without mandibular osteotomy)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 76
Study: 1792820

Group type: COMPARATOR
Intervention: Daflon 500 mg
Number of subjects: 20
Study: 6824358

Group type: EXPERIMENTAL
Intervention: Potent and midstrength topical steroids
Number of subjects: 26

Group type: COMPARATOR
Intervention: Simple lubricating agents
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Irradiated five times weekly
Number of subjects: 26

Group type: COMPARATOR
Intervention: Irradiated three times weekly
Number of subjects: 26
Study: 3902420

Group type: EXPERIMENTAL
Intervention: Aspartame (2.7 g per day for 18 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (identical appearing capsules)
Number of subjects: 62
Study: 31545734

Group type: EXPERIMENTAL
Intervention: Assistive mode
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Perturbing mode
Number of subjects: 24

Group type: COMPARATOR
Intervention: Transparent mode
Number of subjects: 24
Study: 30120406

Group type: EXPERIMENTAL
Intervention: Vitamin D-fortified biscuit (BG)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Capsule vitamin D (CG)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Ampoule vitamin D (AG)
Number of subjects: 108
Study: 26826729

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Frequent drinkers
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Alcohol impairment
Number of subjects: 52
Study: 24906450

Group type: EXPERIMENTAL
Intervention: Community (church)‐based lifestyle intervention programme
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 300
Study: 22878647

Group type: EXPERIMENTAL
Intervention: Vitamin C (1,000 mg/day) and E (400 I.U./day) supplementation for 1 year
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (cholinergic medication only)
Number of subjects: 23
Study: 20197767

Group type: EXPERIMENTAL
Intervention: Internet group (received the letter of invitation)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (did not receive the letter of invitation)
Number of subjects: 115
Study: 18716766

Group type: EXPERIMENTAL
Intervention: 3T MRA with 3D axial inflow technique
Number of subjects: 37

Group type: COMPARATOR
Intervention: 1.5T MRA
Number of subjects: 37

Group type: COMPARATOR
Intervention: Contrast-enhanced MRA (CE-MRA) at 3T
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 3T MRA
Number of subjects: 37
Study: 15832045

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation for 8 weeks from hospital discharge
Number of subjects: 136

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 136
Study: 14634941

Group type: EXPERIMENTAL
Intervention: Mepivacaine 1.5%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ropivacaine 0.75%
Number of subjects: 50
Study: 10747768

Group type: EXPERIMENTAL
Intervention: Telephone interviews
Number of subjects: 100

Group type: COMPARATOR
Intervention: Self-administered diaries
Number of subjects: 100
Study: 9033826

Group type: EXPERIMENTAL
Intervention: Group I: Propofol and fentanyl then isoflurane 1%
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Group 2: TIVA with propofol and fentanyl
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Group 3: Propofol then an epidural lumbar block with bupivacaine 0.25% (single shot) and continuous propofol i.v. infusion
Number of subjects: 36
Study: 1889248

Group type: EXPERIMENTAL
Intervention: D53 (Ribomunyl)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6394515

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (160 mg trimethoprim and 800 mg sulfamethoxazole twice a day for 7 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cefadroxil (500 mg twice a day for 7 days)
Number of subjects: 40
Study: 30784788

Group type: EXPERIMENTAL
Intervention: Myofascial release group (n=18) receiving four sessions of myofascial treatment, each lasting 40 minutes.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (n=18) receiving sham myofascial release.
Number of subjects: 36
Study: 28446232

Group type: EXPERIMENTAL
Intervention: Continuous Quality Improvement (CQI) interventions implemented at facility and health district levels for 18 months.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) teams established at the district and MCH clinic levels.
Number of subjects: 0
Study: 26775208

Group type: EXPERIMENTAL
Intervention: BMP-2 or BMP-7 with autologous bone grafting (24 patients total; 4 with BMP-2, 20 with BMP-7)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Autologous bone grafting without BMP (25 patients)
Number of subjects: 49
Study: 24363039

Group type: EXPERIMENTAL
Intervention: Hip abductor strength training
Number of subjects: 17

Group type: COMPARATOR
Intervention: Arm ergometry
Number of subjects: 17
Study: 21994966

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (average daily dose of 12.0 ± 2.7 mg/m² for PAI; 15.5 ± 7.8 mg/m² for CAH)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: DHEA treatment in PAI women
Number of subjects: 122

Group type: COMPARATOR
Intervention: Non-DHEA treatment in PAI women
Number of subjects: 122
Study: 19118799

Group type: EXPERIMENTAL
Intervention: Pilates exercise regimes (three different types)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stork test (one-legged standing test)
Number of subjects: 0
Study: 17718368

Group type: EXPERIMENTAL
Intervention: Short glide with a 40 ms or less silent gap
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long glide with a 40 ms or less silent gap
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No substitute energy in the gap
Number of subjects: 0
Study: 15098491

Group type: EXPERIMENTAL
Intervention: Community-based health education and health promotion
Number of subjects: 300000

Group type: COMPARATOR
Intervention: Control community
Number of subjects: 300000
Study: 11805744

Group type: EXPERIMENTAL
Intervention: Smoking cessation interventions for women with CVD
Number of subjects: 277
Study: 10593367

Group type: EXPERIMENTAL
Intervention: Crinone 8% (90 mg) once daily
Number of subjects: 86

Group type: COMPARATOR
Intervention: IM progesterone (100 mg) once daily
Number of subjects: 86
Study: 9061429

Group type: EXPERIMENTAL
Intervention: Chronic prostatitis
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Adenoma
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Prostatic neoplasm
Number of subjects: 99

Group type: COMPARATOR
Intervention: Normal levels (control)
Number of subjects: 99
Study: 1711274

Group type: COMPARATOR
Intervention: H1- + H2- antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 0
Study: 6363098

Group type: EXPERIMENTAL
Intervention: Terbutaline 1 mg from a pressurised aerosol
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Terbutaline 1 mg from a nebuliser
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Terbutaline 1 mg from a pressurised aerosol with a pear‐shaped, 750 ml spacer
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Terbutaline 1 mg from a nebuliser with Intermittent Positive Pressure Ventilation (I.P.P.V.)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Terbutaline 4 mg from a nebuliser
Number of subjects: 13
Study: 31533635

Group type: EXPERIMENTAL
Intervention: Health facilities (HFs) readiness index
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Health facilities readiness by district
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Health facilities readiness by level
Number of subjects: 18

Group type: COMPARATOR
Intervention: Comparison of readiness between health facility levels
Number of subjects: 18

Group type: COMPARATOR
Intervention: Difference in readiness between HCIIIs and HCIVs
Number of subjects: 18
Study: 29510423

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) exposure
Number of subjects: 406

Group type: COMPARATOR
Intervention: Control group (normal neurodevelopment)
Number of subjects: 406
Study: 26472295

Group type: EXPERIMENTAL
Intervention: Cooling vest
Number of subjects: 10

Group type: COMPARATOR
Intervention: No vest (Control)
Number of subjects: 10
Study: 25279465

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Idarubicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Matched donor allogeneic transplant
Number of subjects: 0
Study: 22958623

Group type: EXPERIMENTAL
Intervention: Metoprolol succinate (increasing doses to achieve target resting HR <70 beats per minute)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoprolol succinate (increasing doses)
Number of subjects: 20
Study: 20884731

Group type: EXPERIMENTAL
Intervention: Project MYTRI intervention program
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Training teachers
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Higher proportion of students participating in classroom discussions
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Better peer-leader-student communication
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Peer-led health activism
Number of subjects: 32
Study: 18979450

Group type: EXPERIMENTAL
Intervention: Patients with cardiovascular autonomic neuropathy (CAN)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Patients without cardiovascular autonomic neuropathy (CAN)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (18 sex and age-matched healthy adults)
Number of subjects: 39
Study: 16702899

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) administered Hamilton Depression Rating Scale (HAM-D) scores before randomization
Number of subjects: 26168

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) administered Hamilton Depression Rating Scale (HAM-D) scores after randomization
Number of subjects: 26168

Group type: EXPERIMENTAL
Intervention: First-time IVR HAM-D scores before randomization
Number of subjects: 26168
Study: 12806565

Group type: EXPERIMENTAL
Intervention: 12-g piracetam infusion
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (sterile saline)
Number of subjects: 64
Study: 11061765

Group type: EXPERIMENTAL
Intervention: Sumatriptan NS 10 mg
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Sumatriptan NS 20 mg
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Sumatriptan NS 5 mg
Number of subjects: 653
Study: 9358957

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 1543140

Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem (180 mg twice daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2866727

Group type: EXPERIMENTAL
Intervention: Halothane and oxygen
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Nitrous oxide and oxygen
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Premedication a) (pethidine, promethazine, and atropine)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Other premedications
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Premedication a)
Number of subjects: 115
Study: 31878966

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy in Daily Life (ACT-DL) in addition to treatment as usual (TAU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only
Number of subjects: 0
Study: 29866368

Group type: EXPERIMENTAL
Intervention: High-intensity resistance training
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combined moderate-intensity training
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Nitrate-mediated dilation
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Endothelium-dependent and endothelium-independent function of the skin microcirculation
Number of subjects: 62
Study: 26876349

Group type: EXPERIMENTAL
Intervention: Immediate implant placement (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Delayed implant placement (n = 20)
Number of subjects: 40
Study: 25425730

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg/once daily) plus prednisolone (5 mg/twice daily)
Number of subjects: 46
Study: 22377805

Group type: EXPERIMENTAL
Intervention: Active treatment (valgus knee brace, customised neutral foot orthoses, shoes designed for motion control)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control treatment (neutral knee brace, flat unsupportive foot orthoses, shoes with flexible mid‐sole)
Number of subjects: 80
Study: 20855384

Group type: EXPERIMENTAL
Intervention: Home-based intervention to foster child development
Number of subjects: 128

Group type: COMPARATOR
Intervention: Surveillance (control)
Number of subjects: 128
Study: 18286231

Group type: EXPERIMENTAL
Intervention: Cinnarizine (CIN)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Sodium Valproate (SV)
Number of subjects: 125
Study: 16318658

Group type: EXPERIMENTAL
Intervention: 2.3 mL of 0.5% levobupivacaine with fentanyl 15 microg
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2.6 mL of 0.5% levobupivacaine alone
Number of subjects: 50
Study: 14502033

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10797115

Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion (CHO) - 250 ml of an 8% carbohydrate‐electrolyte solution every 15 min
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sweet placebo (Control)
Number of subjects: 11
Study: 8880041

Group type: EXPERIMENTAL
Intervention: Low-fat diet with fish oil supplementation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low-fat diet without fish oil supplementation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Full-fat diet with fish oil supplementation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Full-fat diet without fish oil supplementation
Number of subjects: 32
Study: 7955295

Group type: EXPERIMENTAL
Intervention: CSI lens
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Focus lens
Number of subjects: 63

Group type: COMPARATOR
Intervention: Surevue lens
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Allergic patients
Number of subjects: 63